59 related articles for article (PubMed ID: 31361865)
1. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
2. Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation.
Schapkaitz E; Ter Morshuizen B; Mc Cree M; F Jacobson B
Clin Appl Thromb Hemost; 2024; 30():10760296241249167. PubMed ID: 38659339
[TBL] [Abstract][Full Text] [Related]
3. [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
Melicine S; Maucorps L; Eschwège V; Carré J; Helley D; Gouin-Thibault I; Gendron N; Nédélec-Gac F; Mauge L
Ann Biol Clin (Paris); 2024 Jun; 82(2):129-138. PubMed ID: 38832688
[TBL] [Abstract][Full Text] [Related]
4. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Upreti VV; Wang J; Barrett YC; Byon W; Boyd RA; Pursley J; LaCreta FP; Frost CE
Br J Clin Pharmacol; 2013 Dec; 76(6):908-16. PubMed ID: 23488672
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP).
Zheng R; Lam E; Altshuler P; Crutcher M; Lavu H; Yeo CJ; Stickle D; Leiby B; Kraft WK
Int J Clin Pharmacol Ther; 2024 Jul; 62(7):319-325. PubMed ID: 38660886
[TBL] [Abstract][Full Text] [Related]
6. Complete investigations (autopsy, toxicology, and histology) in a death due to apixaban overdose.
Kintz P; Allain C; Oertel L; Feisthauer E; Ameline A; Raul JS
Int J Legal Med; 2023 Nov; 137(6):1743-1750. PubMed ID: 37542673
[TBL] [Abstract][Full Text] [Related]
7. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Br J Clin Pharmacol; 2020 Aug; 86(8):1632-1641. PubMed ID: 32159869
[TBL] [Abstract][Full Text] [Related]
8. Apixaban for the treatment of acute splanchnic vein thrombosis: A pilot study.
Kim SA; Choi GH; Lee JY; Jang ES; Lee JO; Kim JW; Jeong SH; Bang SM
Thromb Res; 2024 May; 237():181-183. PubMed ID: 38626593
[No Abstract] [Full Text] [Related]
9. DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin.
Melicine S; Habay C; Ghammad W; Carré J; Diehl JL; Smadja DM; Gendron N; Helley D; Mauge L
Int J Lab Hematol; 2024 May; ():. PubMed ID: 38803134
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.
Li Z; Yang S; Hua Z; Lu Y; Li X
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3351-3362. PubMed ID: 37950768
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug-drug interaction between olaparib and apixaban: a case report.
Berge M; Giraud JS; De Percin S; Puszkiel A; Thomas-Schoemann A; Blanchet B
Cancer Chemother Pharmacol; 2024 May; 93(5):519-521. PubMed ID: 37921902
[No Abstract] [Full Text] [Related]
12. Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations.
Luo T; Wang L; Ruan Z; Lou H; Yang D; Wang Z; Zhao P; Jiang B
Clin Transl Sci; 2024 May; 17(5):e13819. PubMed ID: 38747478
[TBL] [Abstract][Full Text] [Related]
13. Lessons for the clinical nephrologist: acute kidney injury during therapy with apixaban.
Vischini G; Speciale S; Przygocka A; Martano L; La Manna G; Baraldi O
J Nephrol; 2024 Mar; 37(2):511-513. PubMed ID: 38055150
[No Abstract] [Full Text] [Related]
14. Massive Apixaban Overdose Confirmed with Blood Concentrations and Managed Without Bleeding: A Single Case Report.
Harmouche E; Stueve P; Howland MA; Su MK
J Pharm Pract; 2024 Jun; 37(3):761-765. PubMed ID: 37227108
[No Abstract] [Full Text] [Related]
15. The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study.
Liu Z; Xie Q; Zhao X; Tan Y; Wang W; Cao Y; Wei X; Mu G; Zhang H; Zhou S; Wang X; Cao Y; Li X; Chen S; Cao D; Cui Y; Xiang Q
Clin Ther; 2024 Apr; 46(4):313-321. PubMed ID: 38553322
[TBL] [Abstract][Full Text] [Related]
16. Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review.
Mendes V; Mamode J; Jolou J; Malki M; Ellenberger C; Cikirikcioglu M; Huber C
J Cardiothorac Surg; 2024 Apr; 19(1):185. PubMed ID: 38582888
[TBL] [Abstract][Full Text] [Related]
17. Managing venous thrombosis in a pediatric patient with short bowel and congenital nephrotic syndromes: a case report emphasizing rivaroxaban level monitoring.
Bosch-Schips M; Artaza G; Hernández-Mata C; Pérez Beltrán V; Cabello Ruiz V; Olivera Sumire P
Front Pediatr; 2024; 12():1385065. PubMed ID: 38633324
[TBL] [Abstract][Full Text] [Related]
18. Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment.
Di Tano G; Moschini L; Loffi M; Testa S; Danzi GB
Eur J Case Rep Intern Med; 2020; 7(7):001790. PubMed ID: 32665940
[TBL] [Abstract][Full Text] [Related]
19. Uncomplicated epidural removal in a patient on a therapeutic heparin infusion: a case report.
Hu L; Adegboye J; Chang AT; Hanna M; Jaremko K
Reg Anesth Pain Med; 2024 May; ():. PubMed ID: 38821537
[TBL] [Abstract][Full Text] [Related]
20. Case report: Severe hepatopathy following rivaroxaban administration in a dog.
Mosichuk AP; Wimbish C; Poplawski K; Birkenheuer A; Harrell K; Pierce KV
Front Vet Sci; 2024; 11():1364677. PubMed ID: 38638638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
